ChromaDex Corp. Files 8-K Report
Ticker: NAGE · Form: 8-K · Filed: Dec 4, 2024 · CIK: 1386570
| Field | Detail |
|---|---|
| Company | Chromadex Corp. (NAGE) |
| Form Type | 8-K |
| Filed Date | Dec 4, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001, $3.5 m |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, other-events
Related Tickers: CDXC
TL;DR
CDXC filed an 8-K for 'Other Events' on Dec 4, 2024. Details TBD.
AI Summary
On December 4, 2024, ChromaDex Corp. filed an 8-K report detailing "Other Events." The filing does not provide specific details on the nature of these events, their financial impact, or any associated dates beyond the filing date itself. Further information would be required to understand the specifics of the reported events.
Why It Matters
This filing indicates a material event has occurred for ChromaDex Corp. that requires public disclosure, though the specific nature of the event is not detailed in this summary.
Risk Assessment
Risk Level: low — The filing is a standard 8-K for 'Other Events' without immediate disclosed financial or operational impact, making the immediate risk level low.
Key Players & Entities
- ChromaDex Corp. (company) — Registrant
- December 4, 2024 (date) — Filing Date
FAQ
What specific event(s) are being reported under 'Other Events' in this 8-K filing?
The provided text for the 8-K filing states the item information is 'Other Events' but does not specify the nature of these events.
Does this 8-K filing disclose any financial impact or dollar amounts related to the reported 'Other Events'?
No, the filing summary does not mention any specific dollar amounts or financial implications associated with the 'Other Events'.
Are there any specific dates mentioned in the filing related to the occurrence or impact of these 'Other Events'?
The filing only explicitly mentions December 4, 2024, as the date of the report and the date of the earliest event reported.
What is the primary purpose of this 8-K filing for ChromaDex Corp.?
The primary purpose is to report 'Other Events' as required by Section 13 or 15(d) of The Securities Exchange Act of 1934.
Where is ChromaDex Corp. headquartered?
ChromaDex Corp.'s principal executive offices are located at 10900 Wilshire Blvd., Suite 600, Los Angeles, California 90024.
Filing Stats: 605 words · 2 min read · ~2 pages · Grade level 14.5 · Accepted 2024-12-04 17:26:23
Key Financial Figures
- $0.001 — ich registered Common Stock, par value $0.001 per share CDXC The Nasdaq Capital Mar
- $3.5 m — tly total an aggregate of approximately $3.5 million, and (ii) that no additional roya
Filing Documents
- cdxc-20241204.htm (8-K) — 20KB
- 0001628280-24-049951.txt ( ) — 140KB
- cdxc-20241204.xsd (EX-101.SCH) — 2KB
- cdxc-20241204_lab.xml (EX-101.LAB) — 21KB
- cdxc-20241204_pre.xml (EX-101.PRE) — 12KB
- cdxc-20241204_htm.xml (XML) — 3KB
01 Other Events
Item 8.01 Other Events On November 27, 2024, ChromaDex, Inc. ("ChromaDex"), a wholly-owned subsidiary of ChromaDex Corporation, entered into a Supplemental Agreement (the "Supplemental Agreement") with the Trustees of Dartmouth College ("Dartmouth," and together with ChromaDex, the "Parties"). The Supplemental Agreement supplements the exclusive license agreements entered into between the Parties dated July 13, 2012 (as amended and restated as of March 13, 2017 and December 29, 2020, the "2012 Agreement") and May 16, 2014 (together with the 2012 Agreement, the "Exclusive License Agreements") pursuant to which ChromaDex received an exclusive license under Dartmouth-owned U.S. patents (the "Dartmouth Patents"). Under the Supplemental Agreement, Dartmouth agreed, subject to certain conditions specified in the Supplemental Agreement and the fulfillment of ChromaDex's obligations under the Agreement, (i) to waive certain accrued but unpaid royalties, license fees, and maintenance expenses owed by ChromaDex under the Exclusive License Agreements, which currently total an aggregate of approximately $3.5 million, and (ii) that no additional royalties, license fees, maintenance or other expenses or other payments will be assessed by Dartmouth or payable by the Company to Dartmouth for the Dartmouth Patents after the effective date of the Agreement. This waiver is contingent upon ChromaDex securing a bond (the "Appeal Bond") for the amount of the fee judgement, if any, related to the previously disclosed Delaware patent infringement case against Elysium Health, Inc. ("Elysium") filed by the Company and Dartmouth relating to the Dartmouth Patents. As of December 3, 2024, ChromaDex executed the Appeal Bond and intends to promptly make an unopposed motion to the court to stay execution of the judgement awarding fees pending the appeal.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CHROMADEX CORPORATION Dated: December 4, 2024 By: /s/ Robert Fried Name: Robert Fried Chief Executive Officer